{"organizations": [], "uuid": "232f885c012449670a594bdde774a4bdb4ec0d22", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "uk.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/Reuters/UKBusinessNews?format=xml", "section_title": "Reuters: Business News", "url": "https://uk.reuters.com/article/uk-vectura-grp-results/drugmaker-vecturas-2017-revenue-rises-17-2-percent-idUKKBN1GX0NE", "country": "US", "domain_rank": 408, "title": "Drugmaker Vectura's 2017 revenue rises 17.2 percent", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-21T09:42:00.000+02:00", "replies_count": 0, "uuid": "232f885c012449670a594bdde774a4bdb4ec0d22"}, "author": "", "url": "https://uk.reuters.com/article/uk-vectura-grp-results/drugmaker-vecturas-2017-revenue-rises-17-2-percent-idUKKBN1GX0NE", "ord_in_thread": 0, "title": "Drugmaker Vectura's 2017 revenue rises 17.2 percent", "locations": [], "entities": {"persons": [{"name": "drugmaker vectura", "sentiment": "none"}, {"name": "sunil nair", "sentiment": "none"}, {"name": "justin george varghese", "sentiment": "none"}], "locations": [{"name": "ultibro", "sentiment": "none"}, {"name": "bengaluru", "sentiment": "none"}], "organizations": [{"name": "drugmaker vectura", "sentiment": "negative"}, {"name": "reuters staff", "sentiment": "none"}, {"name": "skyepharma", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 21, 2018 / 7:43 AM / Updated 8 minutes ago Drugmaker Vectura's 2017 revenue rises 17.2 percent Reuters Staff 1 Min Read (Reuters) - Drugmaker Vectura ( VEC.L ) reported a 17.2 percent rise in 2017 revenue on Wednesday, aided by higher demand for its asthma products Flutiform and Ultibro. The company, which bought rival SkyePharma for 441 million pounds in June 2016, said revenue rose to 148 million pounds in the year ended Dec. 31, compared with 126.3 million pounds, on a proforma basis, a year earlier. Reporting by Justin George Varghese in Bengaluru; Editing by Sunil Nair", "external_links": [], "published": "2018-03-21T09:42:00.000+02:00", "crawled": "2018-03-21T10:05:12.001+02:00", "highlightTitle": ""}